Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: sgx-523, foretinib, telisotuzumab +35 | 1.00 |
| trials ClinicalTrials.gov | 217 Parkinson's trials, 3 stopped | 0.95 |
| literature PubMed | 2,080 Parkinson's papers of 345,700: well-trodden | 0.00 |
| pathways Reactome | 19 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 5285
Sealed predictions
- MET in dopamine neurons, braak+0.20 (p 0.599) → -0.23 (p 0.549)receipt 5293
Swarm cases
receipt 5293: MET in dopamine neurons, braak
- power
- full sample +0.06 (p 0.827, n 18), 95% CI -0.42 to +0.51. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.22 (p 0.379, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.11 (p 0.671, n 18). could be the mix.
- skeptic
- leave-one-out range -0.06 to +0.18, sign flips 4; without severely affected donors +0.06 (p 0.827, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MET in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts